Frequency Therapeutics Inc.
www.frequencytx.com
Latest From Frequency Therapeutics Inc.
Venture Funding Deals: July Sees Seven Rounds Of $100m Or More
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Finance Watch: Cell And Gene Therapy Fundraising Down Overall In Q2, But VC Deals Still Soared
Private Company Edition: ARM's Q2 report shows a 38% decline in financings, but venture capital and upfront fees from deals were robust. Also, Servier raises $405m in the US, Frequency closes a $62m series C and VenatoRx accesses US government cash.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency
Astellas adds a large-market drug candidate to its regenerative medicine portfolio, while Frequency Therapeutics almost doubles its fundraising to date. It traded ex-US rights to hearing loss candidate FX-322 for $80m up front and up to $545m in milestone fees plus royalties.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Dermatology
- Gastrointestinal
- Musculoskeletal & Connective Tissue Disorders
- Otolaryngology
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Start-Up
- Parent & Subsidiaries
- Frequency Therapeutics Inc.
- Senior Management
-
David Lucchino, Pres. & CEO
Chris Loose, PhD, CSO
Dana C Hilt, MD, CMO
Carl Lebel, PhD, Chief Dev. Officer
Ajay Rai, VP, Bus. Dev. - Contact Info
-
Frequency Therapeutics Inc.
Phone: (866) 389-1970
19 Presidential Way
Woburn, MA 01801
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice